



HAL
open science

Estimated Incidence and Prevalence of Serious Fungal Infections in Morocco

Badre Eddine Lmimouni, Christophe Hennequin, Richard O S Penney, David W Denning

► **To cite this version:**

Badre Eddine Lmimouni, Christophe Hennequin, Richard O S Penney, David W Denning. Estimated Incidence and Prevalence of Serious Fungal Infections in Morocco. *Journal of Fungi*, 2022, 8 (4), pp.414. 10.3390/jof8040414 . hal-03727525

HAL Id: hal-03727525

<https://hal.sorbonne-universite.fr/hal-03727525>

Submitted on 19 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Article

2 **Estimated incidence and prevalence of serious fungal infections**
3 **in Morocco**4 **Badre Eddine Lmimouni ¹, Christophe Hennequin ², Richard O.S. Penney ³ and David W. Denning ^{3,4,*}**5 ¹ Parasitology and Medical Mycology laboratory, Military Hospital Teaching Mohammed the fifth, Rabat;
6 Biolnova Research Center, Faculty of Medicine and Pharmacy, University Mohammed the Fifth, Rabat,
7 Morocco; ORCID: 0000-0001-9163-4911; b.lmimouni@um5r.ac.ma8 ² Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine,
9 Service de Parasitologie-Mycologie, F-75012 Paris, France ; ORCID : 0000-0002-4528-927X; chris-
10 tophe.hennequin-sat@aphp.fr11 ³ Global Action For Fungal Infections, Geneva, Switzerland; rpenney@gaffi.org (R.O.S.P.)12 ⁴ Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Man-
13 chester, Manchester, United Kingdom; ORCID: 0000-0001-5626-2251.14 * Correspondence: Professor of Infectious Diseases in Global Health, Manchester Fungal Infection Group, CTF build-
15 ing, Grafton Street, Manchester M13 9NT, United Kingdom ddenning@manchester.ac.uk

16 **Abstract:** Objective: Few data are published from Morocco on fungal disease, although numerous
17 case reports attest to a wide range of conditions in the country. Here we estimate for the first time
18 the incidence and prevalence of serious fungal diseases in the country. Methods: Detailed literature
19 searches in English and French were conducted for all serious fungal infections. Demographic and
20 individual underlying condition prevalence or annual incidence was obtained from UNAIDS (HIV)
21 WHO (TB) and other international sources. Deterministic modelling was then applied to estimate
22 fungal disease burden. Results: Morocco's population in 2021 was 36,561,800. Multiple publications
23 describe various fungal diseases, but epidemiological studies are rare. The most frequent serious
24 fungal infections were tinea capitis (7258/100,000) and recurrent vulvovaginal candidiasis
25 (2794/100,000 females). Chronic pulmonary aspergillosis is also relatively common at 19,290 pre-
26 valence (53/100,000) because of the relatively high rate of tuberculosis. Asthma in adults prevalence
27 exceeds 1 million, of whom fungal asthma (including allergic bronchopulmonary aspergillosis
28 (ABPA)) probably affects 42,150 (115/100,000). Data are scant on candidaemia (estimated at
5/100,000), invasive aspergillosis (estimated at 4.1/100,000), HIV-related complications such as
cryptococcal meningitis and *Pneumocystis* pneumonia and mucormycosis. Fungal keratitis is esti-
mated at 14/100,000). Mycetoma and chromoblastomycosis are probably rare. Conclusion: Fungal
disease is probably common in Morocco and diagnostic capacity is good in the teaching hospitals.
These estimates need confirmation with methodologically robust epidemiological studies.

Citation: Lastname, F.; Lastname, F. *J. Fungi* **2022**, *8*, x30
https://doi.org/10.3390/xxxxx

Academic Editor: Firstname
Lastname

Received: date
Accepted: date
Published: date

Keywords: *Aspergillus*, *Candida*, *Cryptococcus*, *Pneumocystis*, keratitis

Publisher's Note: MDPI stays
neutral with regard to jurisdictional
claims in published maps and
institutional affiliations.



Copyright: © 2022 by the authors.
Submitted for possible open access
publication under the terms and
conditions of the Creative Commons
Attribution (CC BY) license
(https://creativecommons.org/licenses/
by/4.0/).

1. Introduction

Serious fungal infections have generally been increasing in frequency, but lack of diagnosis of many people affected, limits the usefulness of some epidemiological surveys. For example, the diagnosis of invasive aspergillosis is often missed [1] and if the WHO Essential diagnostic tests *Aspergillus* antibody, *Histoplasma* antigen or *Pneumocystis* PCR are not routinely available, then chronic pulmonary aspergillosis, disseminated histoplasmosis and *Pneumocystis* pneumonia will be grossly under-diagnosed. The common lack of diagnosis relegates much fungal disease to clinical oddities and curiosities, while the actual toll that these infections take is under-appreciated. Here, we attempt to show that, in Morocco as in many low or middle incomes countries, many, but not all, fungal diseases are relatively common and need pro-active diagnosis, to be appropriately

47 managed in the clinic.

48 Morocco is a predominantly Muslim country in north Africa with a population of
49 nearly 37 million (11th in Africa) [2]. Split into French and Spanish protectorates in the
50 first half of the 20th century, it has been an independent monarchy since 1956. Morocco's
51 economy is the fifth-largest in Africa by GDP and 13th in terms of GDP per capita [3].

52 There are very few data on the burden of fungal diseases in Morocco, unlike many of
53 the Arab League countries [4]. We have estimated the incidence and prevalence of the
54 most serious fungal diseases, using national, regional and international data in specific
55 populations at risk. Our attempt to collate what is known and published provides a na-
56 tional gap analysis, which can be addressed.

57 2. Methods

58 This literature review was based on articles about fungal infections using the Google
59 Scholar and PubMed/Medline search engines, African newspapers, health reports, epi-
60 demiological journals in Morocco and WHO reports. The articles searched were in Eng-
61 lish and French. The keywords searched were: fungal infection, opportunistic disease,
62 HIV/AIDS, tuberculosis, chronic pulmonary, cryptococcosis, histoplasma, all associated
63 with Morocco. There are few studies on fungal diseases in Morocco. Where no article was
64 found from Morocco or North Africa, we used data from other countries outside the
65 continent.

66 The socio-demographic data were taken from the CIA world fact book [2]. HIV
67 prevalence and AIDS deaths were taken from the 2019 UNAIDS report [5]. We assumed
68 that HIV-infected people not on antiretroviral therapy (ART) develop profound immu-
69 nodeficiency over 7 years (77% of cases are B subtype [6]) and that the rate failure of ART
70 (measured primarily by ART resistance) is 11%. Pulmonary tuberculosis (TB) annual in-
71 cidence was taken from the WHO Global report 2020 [7], and we derived the pulmonary
72 TB survivors. Asthma prevalence in adults was taken from a survey of 10,051 inter-
73 viewees in 14,289 households conducted in 2008 [8]. Chronic obstructive pulmonary
74 disease (COPD) prevalence was derived from the BREATHE study with 10.5% admitted
75 to hospital annually, as in Algeria [9,10]. Lung cancer was taken from Global cancer ob-
76 servatory [11] and acute myeloid leukaemia (AML) from the WHO expert committee on
77 middle income countries [12]. Only renal and autologous bone marrow transplants are
78 performed in Morocco [13]. Liver transplantation has been performed since 2019 (2 at the
79 Military teaching hospital Mohammed the fifth in Rabat and 8 at the Rabat University
80 hospital.

81 The various populations and denominators were used to estimate prevalence or in-
82 cidence of different fungal diseases, as described in other papers [14]. The assumptions
83 used to compute annual incidence or prevalence are also shown.

84 3. Results

85 Morocco's population in 2021 was 36,561,800 of whom 27% are children 14 years old
86 or younger, 9,614,960. There are an estimated 10,256,400 women between the ages of 15
87 and 54 years. In 2020, UNAIDS estimated that 22,000 were living with HIV, of whom
88 about 16,500 are taking ART. There were about 36,000 new cases of tuberculosis in 2020,
89 of which about 18,000 were pulmonary and only 410 had co-infection with HIV. The
90 survival rate of TB is about 93%. Asthma prevalence in adults and children was docu-
91 mented in 2008 at 3.89% of the population, or just over 1 million adults affected. The
92 COPD prevalence (GOLD stage 2-4) was estimated as part of the international BREATHE
93 study and 2.2% of the population were documented with it – a total of 775,980 people, of
94 whom about 84,500 are admitted to hospital each year. There are 7,530 lung cancer cases
95 annually, and about 800 AML cases. Only about 40 renal and 5 allogeneic haematopoietic
96 stem cell transplants are done annually.

Overall, our estimate is that approximately 3,300,000 people in Morocco (9% of the population) suffer from a serious fungal infection. This total is heavily dominated by tinea capitis in children, which is probably common, but perhaps not as common as our estimate.

3.1. Pulmonary fungal diseases

Invasive aspergillosis (IA) was assumed to complicate 13% of AML patients and an equal number of all other haematological malignancies, lymphoma and multiple myeloma, a total of 210 cases of IA annually [15]. An estimated 2.6% of lung cancer patients (n=7,353 in 2020) develop IA [16], a total of 190 patients. Among the 85,450 people with COPD admitted to hospital, 1,100 (1.3%) probably develop IA [17,18]. Overall, the annual incidence of IA is about 1,500 patients (4.1/100,000).

Chronic pulmonary aspergillosis (CPA) may be mistaken for pulmonary TB, be a co-infection during or in the weeks after completion of anti-tuberculous therapy, or may develop in the years after TB cure, especially in this with residual pulmonary cavities. In 2020, 18,360 pulmonary TB cases were reported in Morocco, of whom 8% were not proven, and overall, 3,056 patients died. Many patients with aspergilloma and CPA are described from Morocco, usually in surgical series [19-23]. The estimated annual and post-TB incidence and prevalence are shown in Table 1. This assumes a 19% rate of CPA in undocumented TB cases [24], a 10% rate of CPA at the end of anti-tuberculous therapy and in the

Table 1. The estimated annual caseload (incidence or prevalence) of serious fungal infections in Morocco and number per 100,000 population.

Fungal infection	Predominant Groups at Risk	Rate Per 100,000	Estimated Number of Cases
Cryptococcal meningitis	AIDS	0.43	160
PCP	AIDS	0.53	195
IA	Haematological malignancy, lung cancer and 1.3% of COPD admissions to hospital	4.1	1,500
CPA	Tuberculosis patients and other respiratory disorders	52.8	19,290
ABPA*	Adult asthma patients	71.0	25,950
SAFS*	Adult asthma patients	93.7	34,260
Candidaemia	Hospitalised patients	5.00	1,830
Candida peritonitis	Post-surgical patients	0.75	275
Oesophageal candidiasis	HIV infection	3.7	1,346
Recurrent vaginal candidiasis [#]	Adult women	2794	510,740
Mucormycosis	Multiple, especially diabetes	0.20	73
Fungal keratitis	Corneal injury, contact lens	14.0	5,120
Tinea capitis	4–14-year-old children	7285	2,664,000
Total burden estimated			3,305,100

PCP, Pneumocystis pneumonia; IA, invasive aspergillosis; CPA, chronic pulmonary aspergillosis; ABPA, allergic bronchopulmonary aspergillosis; SAFS, severe asthma with fungal sensitisation;

* Duplication between ABPA and SAFS is likely as both are sensitised to Aspergillus. Fungal asthma total probably 42,150 (115.3/100,000).

Rate per 100,000 females only

6 months after this [25,26], and a 6.5% and 0.2% annual rate in those with and without cavitation at the end of anti-tuberculous therapy (22%) [27,28]. It also assumes a 20% first year mortality of CPA and 7.5% thereafter [29,30]. Overall, annual incidence of CPA related to TB is estimated at 2,482 cases with 165 deaths in the immediate 12 months after first presentation with possible TB. The 5-year period prevalence is estimated at 11,551

with an additional 791 deaths annually. Assuming that TB is the underlying pulmonary condition in 60% of the patients [31], a total CPA prevalence of approximately 19,290 (53/100,000).

The percentage of adults with asthma in 2008 was estimated at 3.89% which means about 1,038,000 affected. Of these, an estimated 26,000 have allergic bronchopulmonary aspergillosis (ABPA) (2.5%) [32]. Assuming that 10% of these asthmatic people have poorly controlled and severe asthma, and that 33% of these people are sensitised to fungi, we estimate that 34,260 have severe asthma with fungal sensitisation (SAFS) [33]. There may be some duplication between these groups, and if this is 30%, then about 42,200 adults have 'fungal asthma' in Morocco (115/100,000). ABPA has been described many years ago in Morocco [34].

A few distinctive cases of fungal rhinosinusitis have been described [35,36]. It is not possible to estimate the burden but if as common as in Israel then 5% of the population may be affected by allergic fungal rhinosinusitis [37].

3.2. HIV-related fungal diseases

Among Morocco's population of HIV patients, an estimated 2,600 in 2020 are at risk of a serious opportunistic infection. While *Pneumocystis* pneumonia has been reviewed as a topic in Morocco [38], data on incidence are lacking. Data has been published some years ago for Tunisia [39]. Assuming an incidence of 15% (a general figure for many countries [40]), an annual incidence in HIV patients is likely to be 195 patients. Cryptococcal meningitis is described in Morocco [41-45]. Cryptococcal meningitis is less frequent at 2.9% (general figure used for the eastern Mediterranean countries) [46] so an estimated 160 patients are likely affected annually. Oesophageal candidiasis is a common problem in HIV patients and assuming that 20% of those with low CD4 counts and 5% of those on ART are affected, it is likely that 1,350 patients are affected at least annually. There are probably a small number of cases of histoplasmosis in Morocco [47-49], but it is not possible to estimate the burden.

3.3. Invasive and superficial candidiasis

Although candidaemia is described in Morocco, few studies collating its incidence are published, and none with a general population denominator. In children with leukaemia, *Candida* spp accounted for 14% of healthcare-associated infections (invasive aspergillosis was not diagnosed) [50]. The risk factors in intensive care include implanted catheters and broad-spectrum antibacterial agents, as in other countries [51]. *Candida albicans*, *C. glabrata* and *C. tropicalis* were the most frequent pathogens. We have assumed a conservative annual incidence of 5/100,000, which converts to about 1,800 cases [52,53]. As in other countries, probably about 33% of cases occur in intensive care, including neonatal and burn units. Using data derived from France, where peritoneal (intra-abdominal) candidiasis is 50% as common as candidaemia in ICU [54], we anticipate 275 cases annually.

Oral and vaginal candidiasis are common problems, but not generally too serious. However, we have estimated the more problematic recurrent vulvovaginal candidiasis in pre-menopausal women, using a 6% rate [55]. This computes to over 510,000 women affected in any one year. One cross-sectional study of 114 consecutive women referred to gynaecology specialist found 22.8% to have a positive microscopy for *Candida* spp. [56]. *Candida albicans* was isolated most frequently (69.2%), followed by *Candida glabrata* and *Candida tropicalis* (15.5% each). The most commonly affected age group was 25–35 years. The literature is silent on recurrent vulvovaginal candidiasis for Morocco.

3.4. Skin and eye infections

Tinea capitis is reported from several series in Morocco [57-62]. A recent meta-analysis of tinea capitis in Africa estimated that 23% in school aged children, or

2,663,557 (95% CI 1,968,716–3,358,398) and 7,285/100,000. This could be an over-estimation, as rates of tinea capitis may be influenced upwards by countries in sub-Saharan Africa.

Mycetoma has been reported infrequently in Morocco over many years [63–69], and the country is above the ‘Mycetoma’ belt [70]. About 50% of the cases are fungal, or eumycetoma [70]. To date 18 cases of chromoblastomycosis have been reported in Morocco [71]. No cases of sporotrichosis have been reported from Morocco.

Mucormycosis is described from Morocco, but is probably uncommon or rare [72–75]. One case of cutaneous mucormycosis in an immunocompetent child has been reported [72], as well as one case of rhinofacial mucormycosis [75]

Fungal keratitis is a serious and often blinding condition, usually related to minor eye injury or wearing of contact lenses. While occasionally reported in Morocco [76,77], no large series have been published. We have therefore used the data from Egypt to estimate annual incidence – 14/100,000 or 5,120 cases.

4. Discussion

In Morocco, life expectancy at birth in women is 74 years and in men is 72 years [78], and 27% of the population is under the age of 15 [2]. There is no compulsory or universal health insurance scheme. In 2007, 16% of the population had some form of medical insurance, including 11% of the population which was covered by public-sector insurers [79]. Most of the population identify as Arabs or Arab-Berbers and are Sunni Muslims. Very few people from sub-Saharan Africa live in Morocco, despite the geographical proximity.

Diagnostic provision in Morocco for fungal diseases is reasonable in teaching hospitals. There are nine University Hospital Centers linked to a School of Medicine and in these hospitals, there are eight Parasitology and Mycology Departments and 16 specialists in topic: in Rabat, Casablanca, Marrakesh, Agadir, Fez, Meknes, Oujda and Tangier. In Laayoune, a university hospital is being developed. The lack of publications of large series of patients reflects a lack of time – clinical and teaching commitments leave little time for surveillance or research.

Diagnostic capacity is good in the teaching centres, with all offering microscopy, culture and histopathology and almost all cryptococcal and *Aspergillus* and *Candida* antigen, as well as *Aspergillus* antibody. *Pneumocystis* PCR is only available in Casablanca and Rabat, and *Histoplasma* antigen testing is not available. It is not clear if the country has cases of histoplasmosis in humans (as opposed to the relatively frequent equine histoplasmosis (epizootic lymphangitis) caused by a separate sub-species *H. farciminosum*). Opportunities exist from strengthening capacity with external funds from, for example, the Global Fund for AIDS, TB and Malaria [80].

The major limitation to this work is the lack of large studies from the country. Almost all the estimates are inferences. For example we found only one paper on vulvovaginal candidiasis and none on recurrent disease, yet it is unlikely that Moroccan women are immune to this troublesome complaint. There are considerable bodies of work on chronic pulmonary aspergillosis and aspergilloma, principally surgical series, with a note that this disorder is relatively frequent. There are multiple publications focused on HIV infection, but less on the complications of AIDS. Several Moroccan authors have summarised the clinical approach to particular conditions, such as *Pneumocystis* pneumonia, chronic pulmonary aspergillosis indicative of local awareness of these conditions.

The estimation approach to chronic pulmonary aspergillosis differs from prior estimates which have primarily focussed on post-anti-tuberculous CPA. Here we have included estimates of misdiagnosed TB (which is probably a numerically small problem in Morocco as 94% of cases are confirmed bacteriologically), and cases occurring during and immediately after therapy. Again all the assumptions made are based on studies from

other countries and given genetic components to CPA susceptibility, these estimates are likely to be inaccurate. They require local studies to be done.

The very large numbers of children with tinea capitis may well be an over-estimation. In the one study from Morocco, 18% of children attending hospital had tinea capitis, but this is clearly a select population.

This survey supports previous reports from other north-African countries that about 9% of Moroccan inhabitants suffer from fungal infections. The most important by their incidence/prevalence are pulmonary fungal infections (mostly *Aspergillus* diseases) and superficial (tinea capitis) and mucosal (vulvo-vaginal candidiasis). These population-based data should promote the implementation of a fungal surveillance system to describe more precisely the landscape of these infections that should drive some public health care policy.

Author Contributions: This article was conceived by DWD in accord with a long-term program of estimating the burden of serious fungal disease in each country. All four authors contributed to the data generation, reference acquisition, analysis and writing process. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partially supported by Gilead Sciences, who had no input into the content.

Institutional Review Board and Ethics Statement: Not applicable.

Data Availability Statement: All applicable data is published and referenced in the paper.

Acknowledgments: None

Conflicts of Interest: The authors report no conflicts of interest.

References

1. Danion, F.; Rouzaud, C.; Duréault, A.; Poirée, S.; Bougnoux, M.E.; Alanio, A.; Lanternier, F.; Lortholary, O. Why are so many cases of invasive aspergillosis missed? *Med Mycol*, **2019**, *Apr 1*;57(Supplement_2), S94-S103.
2. Central Intelligence Agency. CIA World Factbook. Available online: <https://www.cia.gov/the-world-factbook/> (accessed on 1 July 2021)
3. International Monetary Fund. Report for Selected Countries and Subjects. Available online: <https://www.imf.org/en/Publications/WEO/weo-database/2021/April/weo-report> (accessed on 1 July 2021).
4. Kmeid, J.; Jabbour, J.F.; Kanj, S.S. Epidemiology and burden of invasive fungal infections in the countries of the Arab League. *J Infect Public Health*, **2020**, *Dec*;13(12), 2080-2086.
5. UNAIDS data 2019. Available online: <https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data> (accessed on 10 January 2021).
6. Akrim, M.; Lemrabet, S.; Elharti, E.; Gray, R.R.; Tardy, J.C.; Cook, R.L.; Salemi, M.; Andre, P.; Azarian, T.; Aouad, R.E. HIV-1 Subtype distribution in Morocco based on national sentinel surveillance data 2004-2005. *AIDS Res Ther*, **2012**, *Feb 14*;9(1), 5.
7. World Health Organisation. Global Tuberculosis Report 2020. Available online: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22MA%22 (accessed on 20 February 2022).
8. Nafti, S.; Taright, S.; El Ftouh, M.; Yassine, N.; Benkheder, A.; Bouacha, H.; Fakhfakh, H.; Ali-Khoudja, M.; Texier, N.; El Hasnaoui, A. Prevalence of asthma in North Africa: the Asthma Insights and Reality in the Maghreb (AIRMAG) study. *Respir Med*, **2009**, *103*, S2-S11; DOI:10.1016/S0954-6111(09)70022-8.
9. Polatli, M.; Ben Kheder, A.; Wali, S.; Javed, A.; Khattab, A.; Mahboub, B.; Iraqi, G.; Nejari, C.; Taright, S.; Koniski, M.; Rashid, N.; El Hasnaoui, A. Chronic obstructive pulmonary disease and associated healthcare resource consumption in the Middle East and North Africa: The BREATHE study. *Respir Med*, **2012**, *106*, S75-S85.
10. Tageldin, M.; Nafti, S.; Khan, J.; Nejari, C.; Beji, M.; Mahboub, B.; Obeidat, N.; Uzaslan, E.; Sayiner, A.; Wali, S.; Rashid, N.; El Hasnaoui, A. Distribution of COPD-related symptoms in the Middle East and North Africa: Results of the BREATHE study. *Respir Med*, **2012**, *106*, S25-S32.
11. The Global Cancer Observatory. Morocco Fact Sheet. Available online: <https://gco.iarc.fr/today/data/factsheets/populations/504-morocco-fact-sheets.pdf> (accessed on 20 February 2022).
12. Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. Acute Myelogenous Leukemia. Available online: https://www.who.int/selection_medicines/committees/expert/20/applications/AML_APL.pdf (accessed on 20 February 2022).
13. International Registry in Organ Donation and Transplantation. Transplant data. Available online: <https://www.irodat.org/?p=databse&c=MA&year=2020#data> (accessed on 20 February 2022).

- 285 14. Wahyuningsih, R.; Adawiyah, R.; Sjam, R.; Prihartono, J.; At Wulandari, E.; Rozaliyani, A.; Ronny, R.; Imran, D.; Tugiran, M.;
286 Siagian, F.E.; Denning, D.W. Serious fungal disease incidence and prevalence in Indonesia. *Mycoses*, **2021**, *64*, 1203–12.
- 287 15. Lortholary, O.; Gangneux, J.P.; Sitbon, K.; et al. Epidemiological trends in invasive aspergillosis in France: The SAIF network
288 (2005–2007). *Clin Microbiol Infect*, **2011**, *17*(12), 1882–1889.
- 289 16. Yan, X.; Li, M.; Jiang, M.; et al. Clinical characteristics of 45 patients with invasive pulmonary aspergillosis: retrospective
290 analysis of 1711 lung cancer cases. *Cancer*, **2009**, *115*(21), 5018–5025.
- 291 17. Guinea J.; Torres-Narbona, M.; Gijón, P.; et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary dis-
292 ease: incidence, risk factors, and outcome. *Clin Microbiol Infect*, **2010**, *16*(7), 870–877.
- 293 18. Hammond, E.E.; McDonald, C.S.; Vestbo, J.; Denning, D.W. The global impact of Aspergillus infection on COPD. *BMC Pulm*
294 *Med*, **2020**, *20*, 241.
- 295 19. Harmouchi, H.; Sani, R.; Issoufou, I.; Lakranbi, M.; Ouadnoui, Y.; Smahi, M. Pulmonary aspergilloma: from classification to
296 management. *Asian Cardiovasc Thorac Ann*, **2020**, *Jan*;28(1), 33–38.
- 297 20. Harmouchi, H.; Lakranbi, M.; Issoufou, I.; Ouadnoui, Y.; Smahi, M. Pulmonary aspergilloma: surgical outcome of 79 patients
298 in a Moroccan center. *Asian Cardiovasc Thorac Ann*, **2019**, *Jul*;27(6), 476–480.
- 299 21. El Hammoumi, M.M.; Slaoui, O.; El Oueriachi, F.; Kabiri, E.H. Lung resection in pulmonary aspergilloma: experience of a
300 Moroccan center. *BMC Surg*, **2015**, *Oct 16*, 15:114.
- 301 22. Benjelloun, H.; Zaghba, N.; Yassine, N.; Bakhatar, A.; Karkouri, M.; Ridai, M.; Bahlaoui, A. Chronic pulmonary aspergillosis: a
302 frequent and potentially severe disease. *Med Mal Infect*, **2015**, *Apr*;45(4), 128–32.
- 303 23. Kabiri, H.; Lahlou, K.; Achir, A.; al Aziz, S.; el Meslout, A.; Benosman, A. Pulmonary aspergilloma: results of surgical treat-
304 ment. Report of a series of 206 cases. *Chirurgie*, **1999**, *Dec*;124(6), 655–60.
- 305 24. Oladele, R.O.; Irurhe, N.K.; Foden, P.; Akanmu, A.S.; Gbaja-Biamila, T.; Nwosu, A.; Ekundayo, H.A.; Ogunsola, F.T.; Rich-
306 ardson, M.D.; Denning, D.W. Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in
307 Nigerians. *Int J Tuberc Lung Dis*, **2017**, *21*, 1056–61.
- 308 25. Setianingrum, F.; Rozaliyani, A.; Syam, R.; Adawiyah, R.; Tugiran, M.; Sari, C.Y.I.; Burhan, E.; Wahyuningsih, R.;
309 Rautemaa-Richardson, R.; Denning, D.W. Evaluation and comparison of automated and manual ELISA for diagnosis of
310 chronic pulmonary aspergillosis (CPA) in Indonesia. *Diagn Microbiol Infect Dis*, **2020**, *98*, 115124.
- 311 26. Setianingrum, F.; Rozaliyani, A.; Adawiyah, R.; et al. A prospective longitudinal study of chronic pulmonary aspergillosis in
312 pulmonary tuberculosis in Indonesia (APICAL). *Thorax Epub*, **2021**, *0*, 1–8; DOI:10.1136/thoraxjnl-2020-216464.
- 313 27. Page, I.D.; Byanyima, R.; Hosmane, S.; Onyachi, N.; Opira, C.; Opwonya, J.; Richardson, M.D.; Sawyer, R.; Sharman, A.; Den-
314 ning, D.W. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.
315 *Eur Resp J*, **2019**, *53*, 1801184.
- 316 28. Denning, D.W.; Pleuvry, A.; Cole, D.C. Global burden of chronic pulmonary aspergillosis as a sequel to tuberculosis. *Bull*
317 *WHO*, **2011**, *89*, 864–72.
- 318 29. Ohba, H.; Miwa, S.; Shirai, M.; Kanai, M.; Eifuku, T.; Suda, T.; Hayakawa, H.; Chida, K. Clinical characteristics and prognosis of
319 chronic pulmonary aspergillosis. *Respir Med*, **2012**, *May*;106(5), 724–9.
- 320 30. Maitre, T.; Cottenet, J.; Godet, C.; Roussot, A.; Abdoul Carime, N.; Ok, V.; Parrot, A.; Bonniaud, P.; Quantin, C.; Cadranet, J.
321 Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis. *Eur Respir J*, **2021**, *Aug 19*;58(2),
322 2003345.
- 323 31. Smith, N.; Denning, D.W. Underlying pulmonary disease frequency in patients with chronic pulmonary aspergillosis. *Eur Resp*
324 *J*, **2011**, *37*, 865–72.
- 325 32. Al-Mobeireek, A.F.; El-Rab, M.O.G.; Al-Hedaithy, S.S.; et al. Allergic bronchopulmonary mycosis in patients with asthma:
326 period prevalence at a university hospital in Saudi Arabia. *Respir Med*, **2001**, *95*, 341–347.
- 327 33. Denning, D.W.; Pashley, C.; Hartl, D.; Wardlaw, A.; Godet, C.; Del, Giacco, S.; Delhaes, L.; Sergejeva, S. Fungal allergy in
328 asthma—state of the art and research needs. *Clin Transl Allergy*, **2014**, *4*, 14.
- 329 34. Bensouda, A. Aspects of broncho-pulmonary aspergillosis in Morocco. Apropos of 11 cases. *Maroc Med*, **1974**, *Nov*;54(584),
330 612–30.
- 331 35. Boutarbouch, M.; Arkha, Y.; El Ouahabi, A.; Derraz, S.; El Khamlichi, A. Sphenoid sinus aspergillosis simulating pituitary
332 tumor in immunocompetent patient. *J Clin Neurosci*, **2009**, *Jun*;16(6), 840–1.
- 333 36. Bijou, W.; Abdulhakeem, B.; Choukry, K.; Oukessou, Y.; Rouadi, S.; Abada, R.; Roubal, M.; Mahtar, M. Unusual Location of a
334 Fungus Ball: The Concha Bullosa, a Review of the Literature. *Allergy Rhinol (Providence)*, **2021**, *12*, 21526567211036146.
- 335 37. Ben-Ami, R.; Denning, D.W. Estimating the burden of fungal diseases in Israel. *Israel Med Assc J*, **2015**, *17*, 374–9.
- 336 38. Herrag, M.; Elfassy Fihry, M.T.; Alaoui Yazidi, A. [Pneumocystis jirovecii: what does this mean?]. *Rev Pneumol Clin*, **2010**,
337 *Dec*;66(6), 342–6; DOI:10.1016/j.pneumo.2009.09.007.
- 338 39. Ennalfer-Jerbl, E.; Louzir, B.; Huerre, M.; Beji, M.; Tiouiri, H.; Daghfous, J.; Ben Chaabane, T.; Boubaker, S. Frequency of
339 Pneumocystis carinii pneumonia in HIV-infected patients in Tunisia. *Tunis Med*, **2002**, *80*, 29–32.
- 340 40. Bongomin, F.; Gago, S.; Oladele, R.O.; Denning, D.W. Global and national prevalence of fungal diseases – Estimate precision. *J*
341 *Fungi*, **2017**, *3*, E57.
- 342 41. Aoufi, S.; Agoumi, A.; Seqat, M. Cryptococcal neuromeningitis in immunosuppressed subjects at Rabat University Hospital
343 (Morocco). *Ann Biol Clin (Paris)*, **2008**, *Jan-Feb*;66(1), 79–81.

- 344 42. Sodqi, M.; Marih, L.; Lahsen, A.O.; Bensghir, R.; Chakib, A.; Himmich, H.; El Filali, K.M. Causes of death among 91
345 HIV-infected adults in the era of potent antiretroviral therapy. *Presse Med*, **2012**, *Jul*;41(7-8), e386-90.
- 346 43. Dollo, I.; Marih, L.; El Fane, M.; Es-Sebbani, M.; Sodqi, M.; Oulad Lahsen, A.; Chakib, A.; El Kadioui, F.; Hamdani, A.; El
347 Mabrouki, M.J.; Soussi Abdallaoui, M.; Karima, Z.; Hassoune, S.; Maaroufi, A.; Marhoum El Filali, K. Retrospective study of
348 neuromeningeal cryptococcosis in patients infected with HIV in the infectious diseases unit of university hospital of Casa-
349 blanca, Morocco. *J Med Mycol*, **2016**, *Dec*;26(4), 331-336.
- 350 44. El Fane, M.; Sodqi, M.; Lamdini, H.; Marih, L.; Lahsen, A.O.; Chakib, A.; El Filali, K.M. Central Neurological Diagnosis in
351 Patients Infected with HIV in the Infectious Diseases Unit of University Hospital of Casablanca, Morocco. *Bull Soc Pathol Exot*,
352 **2018**, *111*(1), 24-30.
- 353 45. Bandadi, F.Z.; Raiss, C.; Moustachi, A.; Lyagoubi, M.; Aoufi, S. Forty cases of neuromeningeal cryptococcosis diagnosed at the
354 Mycology-Parasitology Department of the Ibn Sina hospital in Rabat, over a 21-year period. *Pan Afr Med J*, **2019**, *Jul* 23;33, 249.
- 355 46. Rajasingham, R.; Smith, R.M.; Park, B.J.; Jarvis, J.N.; Denning, D.W.; Govender, N.P.; Loyse, A.; Boulware, D.R. Global burden
356 of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis*, **2017**, *17*, 873-81.
- 357 47. Chihab, W.; Achergui, A.; Agoumi, A.; Chraïbi, H.; Hassam, B.; Mansouri, F. [American histoplasmosis: a case with cutaneous
358 presentation in Morocco]. *Med Trop (Mars)*, **2003**, *63*(2), 171-4.
- 359 48. Tazi, E.M.; Essadi, I.; Serraj, K.; Ichou, M.; Errihani, H. Histoplasmosse sacrée dix ans après un lymphome non hodgkinien du
360 sacrum : à propos d'un cas. *Cancer/Radiothérapie [Internet]*. **2009**, *Jul*;13(4), 337-9.
- 361 49. Elansari, R.; Abada, R.; Rouadi, S.; Roubal, M.; Mahtar, M. Histoplasma capsulatum sinusitis: Possible way of revelation to the
362 disseminated form of histoplasmosis in HIV patients. *Int J Surg Case Rep*, **2016**, *24*, 97-100; DOI:10.1016/j.ijscr.2016.03.010.
- 363 50. Cherkaoui, S.; Lamchahab, M.; Samira, H.; Zerouali, K.; Madani, A.; Benckekroun, S.; Quessar, A. Healthcare-associated infec-
364 tions in a paediatric haematology/oncology unit in Morocco. *Sante Publique*, **2014**, *Mar-Apr*;26(2), 199-204.
- 365 51. Massou, S.; Ahid, S.; Azendour, H.; Bensghir, M.; Mounir, K.; Iken, M.; Lmimouni, B.E.; Balkhi, H.; Drissi Kamili, N.; Haimeur,
366 C. Systemic candidiasis in medical intensive care unit: analysis of risk factors and the contribution of colonization index. *Pathol*
367 *Biol (Paris)*, **2013**, *61*(3), 108-12.
- 368 52. Arendrup, M.C. Epidemiology of invasive candidiasis. *Curr Opin Crit Care*, **2010**, *16*, 445-52;
369 DOI:10.1097/mcc.0b013e32833e84d2.
- 370 53. Cleveland, A.A.; Farley, M.M.; Harrison, L.H.; et al. Changes in incidence and antifungal drug resistance in candidemia: results
371 from population-based laboratory surveillance in Atlanta and Baltimore, 2008- 2011. *Clin Infect Dis*, **2012**, *55*, 1352-61.
- 372 54. Montravers, P.; Mira, J.P.; Gangneux, J.P.; Leroy, O.; Lortholary, O.; AmarCand study group. A multicentre study of antifungal
373 strategies and outcome of Candida spp. peritonitis in intensive-care units. *Clin Microbiol Infect*, **2011**, *Jul*;17(7), 1061-7.
- 374 55. Denning, D.W.; Kneale, M.; Sobel, J.D.; Rautemaa-Richardson, R. Global burden of recurrent vulvovaginal candidiasis. *Lancet*
375 *Infect Dis*, **2018**, *18*, e339-e347.
- 376 56. Benchellal, M.; Guelzim, K.; Lemkhente, Z.; Jamili, H.; Dehainy, M.; Rahali Moussaoui, D.; El Mellouki, W.; Sbai Idrissi, K.;
377 Lmimouni, B. Vulvovaginal candidiasis in the military teaching hospital Mohammed the fifth (Morocco). *J Mycol Med*, **2011**,
378 *21*(2), 106-112.
- 379 57. Oudaina, W.; Biougnach, H.; Riane, S.; El Yaagoubil, I.; Tangi, R.; Ajdae, L.; Agoumi, A.; Tligui, H. Epidemiology of tinea
380 capitis in outpatients at the Children's Hospital in Rabat (Morocco). *J Mycol Med*, **2011**, *Mar*;21(1), 1-5.
- 381 58. Boumhil, L.; Hjira, N.; Naoui, H.; Zerrou, A.; Bhirich, N.; Sedrati, O.; El Mellouki, W.; Lmimouni, B. Tinea capitis in the mili-
382 tary hospital Mohammed V (Morocco). *J Mycol Med*, **2010**, *20* (2), 97-100.
- 383 59. Elmaataoui, A.; Zeroual, Z.; Lyagoubi, M.; Aoufi, S. Tinea capitis etiology in Ibn Sina Hospital in Rabat (Morocco). *J Mycol Med*,
384 **2012**, *Sep*;22(3), 261-4.
- 385 60. El Mezouari, E.; Hocar, O.; Atarguine, H.; Akhdari, N.; Amal, S.; Moutaj, R. Tinea capitis in the military hospital Avicenna
386 (Morocco): Review of 8 years (2006-2013). *J Mycol Med*, **2016**, *Mar*;26(1), e1-5.
- 387 61. Halim, I.; El Kadioui, F.; Soussi Abdallaoui, M. Mycological and epidemiological aspects of tinea capitis in ibn rochd university
388 hospital center, Casablanca (Morocco). *J Med Mycol*, **2012**, *50*(4), 418-422.
- 389 62. Aqil, N.; BayBay, H.; Moustaide, K.; Douhi, Z.; Elloudi, S.; Mernissi, F.Z. A prospective study of tinea capitis in children:
390 making the diagnosis easier with a dermoscope. *J Med Case Rep*, **2018**, *Dec* 28;12(1), 383.
- 391 63. Amrani, F.E.; Hassam, B. 'Le pied de Madura'. *Pan Afr Med J*, **2013**, *14*, 24; DOI: 10.11604/pamj.2013.14.24.2381.
- 392 64. Asly, M.; Razaoui, A.; Bouyermane, H.; et al. Mycetoma (Madura foot): A case report. *Ann Phys Rehabil Med*, **2010**, *53*(10),
393 650-654.
- 394 65. Baha, H.; Khadir, K.; Hali, F.; et al. Mycétome actinomycosique du pied à Actinomyces viscosus au Maroc, *J Mycol Med*, **2015**,
395 *25*(1), 76-80.
- 396 66. Bouhamidi, A.; Boui, M. Madura foot: a case report. *Pan Afr Med J*, **2018**, *30*, 131.
- 397 67. Efaled, B.; Tahiri, L.; Boubacar, M.S.; et al. Mycetoma in a non-endemic area: a diagnostic challenge. *BMC Clin Pathol*, **2017**,
398 *17*(1), 1-6.
- 399 68. Marc, S.; Meziane, M.; Hamada, S. Clinique et épidémiologie des mycétomes au Maroc. *Med Mal Infect*, **2011**, *41*(3), 163-164;
400 DOI:10.1016/j.medmal.2010.11.006.
- 401 69. Messoudi, A.; Fnini, S.; El Andaloussi, Y.; et al. Le pied de Madura: pathologie rare au Maroc (à propos de 15 cas). *Bull Soc Path*
402 *Ex*, **2013**, *106*(9), 9-12.
- 403 70. Emery, D.; Denning, D.W. The global distribution of actinomycetoma and eumycetoma. *PLoS NTD*, **2020**, *14*, e0008397.

- 404 71. Santos, D.W.C.L.; de Azevedo, C.M.P.; Queiroz-Telles, F.; Vicente, V.A.; Rodrigues, A.M.; de Hoog, G.S.; Denning, D.W.;
405 Colombo, A.L. The global burden of chromoblastomycosis. *PLoS NTD*, **2021**, *15*(8), e0009611.
- 406 72. Razouk, S.; Sebbani, S.; Agoumi, A.; Benouchen, T.; Malihi, A.; Nacir, A.; Abouhafsse, A.; Al Hamany, Z.; Tligui, H. The sub-
407 cutaneous mucormycosis due to *Lichtheimia corymbifera*: A case report in an immunocompetent child. *J Mycol Med*, **2012**,
408 *Jun*;22(2), 185-8.
- 409 73. Lmekki, S.; Zaki, Z.; El Alami, M.N. Rhinocerebral mucormycosis. *Med Mal Infect*, **2012**, *42*(4), 171-3.
- 410 74. Razem, B.; Dennai, Y.; Slimani, F. Chronical rhino-orbital mucormycosis in an immunocompetent host: A case report. *Int J Surg*
411 *Case Rep*, **2021**, *82*, 105882.
- 412 75. Abilkassim, R.; Dini, N.; En-Nouali, H.; Lemkhente, Z.; Agadr, A.; Lmimouni, B. Rhinofacial mucormycosis : A case report. *J*
413 *Mycol Med*, **2011**, *21*(1), 51-54.
- 414 76. Er-Rami, M.; Souhail, H.; Lemkhente, Z.; El Mellouki, W.; Lmimouni, B. Severe keratomycosis due to *Fusarium solani* induced
415 by a telluric foreign body: About a case in Moroccan Sahara. *J Mycol Med*, **2011**, *21*(3), 206-209;
416 DOI:10.1016/j.mycmed.2011.05.001.
- 417 77. Elouarradi, H.; Cherkaoui, L.O. Corneal ectasia following keratomycosis. *Pan Afr Med J*, **2014**, *Mar 27*, 17:229.
- 418 78. World Health Organisation. Life expectancy at birth (years). Available online:
419 [https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-\(years\)](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-(years)) (accessed on 20 Febru-
420 ary 2022).
- 421 79. Ruger, J.P.; Kress, D. Health financing and insurance reform in Morocco. *Health affairs (Project Hope)*, **2007**, *26*(4), 1009–1016;
422 DOI:10.1377/hlthaff.26.4.1009.
- 423 80. Bolan, N.; Azzouzi, A.; Alami, K.; Alaoui, A.; Hachri, H.; Latifi, A.; Ferenchick, E.; Mangiaterra, V.; Murray, S.; Shakarishvili,
424 G.; Souteyrand, Y. Leveraging Global Fund investments for health systems strengthening: a qualitative case study on Moroc-
425 co's Concept Note development. *East Mediterr Health J*, **2020**, *Aug 25*;26(8), 957-966.